Kalaris (KLRS) VP Amy O'Leary Vandekop Receives Option Award

What Happened
Vandekop Amy O'Leary, VP and Corporate Controller of Kalaris Therapeutics (KLRS), was granted a derivative award on August 27, 2026 for 10,000 shares (reported at $0). The filing lists this as an award/grant (Form 4 code A); there was no cash paid and the reported transaction value is $0.

Key Details

• Transaction date: August 27, 2026; Form 4 filed August 28, 2026 (appears timely).
• Security: derivative award (option) for 10,000 shares, reported price $0.00, total reported value $0.
• Vesting: 4-year schedule — 25% of underlying shares vest on August 1, 2027, remainder vest in equal monthly installments thereafter, subject to continuous service (footnote).
• Shares owned after transaction: not specified in the filing.
• Transaction type code: A = Award/Grant.

Context
This was a grant of an equity award (option/derivative) rather than a market purchase or sale. No shares were sold or bought on the open market and no immediate cash changed hands. Vesting is time-based and contingent on continued service, so the award does not represent immediately tradable shares.